Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

Archives of Pediatrics and Adolescent Medicine 2026 Open access

Read full text
Authors: Maria Sckaff, Ilina C. Odouard, Jeromie M. Ballreich, Gerard F. Anderson, Mariana P. Socal
DOI: 10.1001/jamapediatrics.2026.0641
Cited by: 1
References: 2

Abstract

This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Fields of Study & Subjects

Neurogenetic and Muscular Disorders Research Hereditary Neurological Disorders Amyotrophic Lateral Sclerosis Research

Publication details

Journal / source
Archives of Pediatrics and Adolescent Medicine
Publisher
American Medical Association (AMA)
Volume
180
Issue
6
Pages
695–695
Publication date
13 April 2026
Language
EN